Share on StockTwits

Aegerion Pharmaceuticals (NASDAQ:AEGR) released its earnings data on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.30) by $0.16, Analyst Ratings Net reports. The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $24.51 million.

AEGR has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Aegerion Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, January 14th. They now have a $50.70 price target on the stock. Analysts at Cowen and Company cut their price target on shares of Aegerion Pharmaceuticals from $105.00 to $95.00 in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $96.64.

Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 66.35 on Wednesday. Aegerion Pharmaceuticals has a 52-week low of $29.06 and a 52-week high of $101.00. The stock’s 50-day moving average is $62.60 and its 200-day moving average is $76.01. The company’s market cap is $1.940 billion.

Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.